Associated Papers
The impact of the solute carrier gene superfamily polymorphisms on tyrosine kinase inhibitors responses among chronic myeloid leukemia: A meta-analysis.
Thuy VT et al.
Leukemia Research, 2025
Population pharmacokinetics and pharmacogenetics analyses of imatinib in Chinese patients with chronic myeloid leukemia in a real-world situation.
He S et al.
Cancer Chemotherapy and Pharmacology, 2023
Genetic Variants of ABC and SLC Transporter Genes and Chronic Myeloid Leukaemia: Impact on Susceptibility and Prognosis.
Alves R et al.
International Journal of Molecular Sciences, 2022
36077209 (PubMed )
Supplement: ijms-23-09815-s001.zip › ijms-1852648-supplementary.pdf
Influence of genetic variants and antiepileptic drug co-treatment on lamotrigine plasma concentration in Mexican Mestizo patients with epilepsy.
Ortega-Vázquez A et al.
The Pharmacogenomics Journal, 2020
Patient profiling in diabetes and role of canagliflozin.
Amblee A
Pharmacogenomics and Personalized Medicine, 2014
Genetic variation and response to morphine in cancer patients: catechol-O-methyltransferase and multidrug resistance-1 gene polymorphisms are associated with central side effects.
Ross JR et al.
Cancer, 2008
Implications of genetic polymorphisms in drug transporters for pharmacotherapy.
Kerb R
Cancer Letters, 2006
Select a paper to view details